On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online in the New England Journal of Medicine.

The trial was lconducted at Kaiser Permanente Washington Health Research Institute in Seattle, where the first participant received the candidate vaccine Mar. 16. This interim report detailed the initial findings from the first 45 participants ages 18 to 55 years enrolled at the study sites in Seattle and at Emory University in Atlanta. T